We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Crystal Structure Determined for Binding Site of Zika/Dengue Neutralizing Antibodies

By LabMedica International staff writers
Posted on 05 Jul 2016
An international team of molecular virologists has identified neutralizing antibodies that bind to and block both dengue virus and Zika virus, which may pave the way for development of a vaccine to protect against both viruses simultaneously.

The international team, headed by investigators at Institut Pasteur (Paris, France), examined the effect of two antibodies isolated from dengue patients on the Zika virus.

They reported in the June 23, 2016, online edition of the journal Nature that one of the antibodies was even better at neutralizing the Zika virus than it was at neutralizing dengue virus. More...
The X-ray crystal structure of the antibody in complex with the envelope protein of Zika virus revealed details of a conserved epitope, which was also the site of interaction of the envelope protein dimer with the precursor prM protein during virus maturation. This binding site on the Zika virus is the same as the one on the dengue virus, raising the possibility of producing a vaccine that would stimulate the production of antibodies capable of binding to and neutralizing both types of virus at the same time.

"We wanted to see whether the antibodies isolated for dengue could be used to neutralize other flaviviruses, and Zika seemed like the best candidate," said senior author Dr. Félix Rey, head of the structural virology laboratory at the Institut Pasteur. "We never expected to discover that the dengue virus and the Zika virus are so close that some antibodies produced against the dengue virus could also neutralize the Zika virus so potently. The antibodies could be used, for example, to protect pregnant women at risk of contracting the Zika virus, because there is currently no vaccine or treatment for this disease."

Related Links:
Institut Pasteur


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.